CURASIGHT A/S
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications. The Company has developed a highly specific PET (Positron emission tomography) imaging ligand, uTRACE®, targeting the receptor uPAR, which is a biomarker only expressed in cancer. uTRACE® will become a game-changer in the diagnosis and treatment of cancer patients. In addition, with the promising results obtained within diagnostics Curasight will also pursues uPAR ... targeted radionuclide therapy using the uTREAT® ligand. As PET imaging and radionuclide therapy is based on the same uPAR binding peptide, a uTRACE® scan can precisely predict where subsequent targeted radiation therapy will be delivered. uTRACE® covers the diagnostic path and uTREAT® covers the therapy. This will be the new management and treatment of cancer patients in the future.
CURASIGHT A/S
Industry:
Biotechnology Collaboration Pet
Founded:
2013-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.curasight.com
Total Employee:
1+
Status:
Active
Contact:
+45 22830160
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Nginx Microsoft Exchange Online Office 365 Mail
Similar Organizations
GoodGut
GoodGut is a biotech company dedicated to designing products for supporting the diagnosis and treatment of digestive diseases
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Vetigenics
Vetigenics discovers and develops antibody-based immunotherapies to treat cancer and chronic diseases in companion animals
Current Employees Featured
Founder
Stock Details
Investors List
Seed Capital
Seed Capital investment in Seed Round - Curasight A/S
PreSeed Ventures
PreSeed Ventures investment in Seed Round - Curasight A/S
Seed Capital
Seed Capital investment in Seed Round - Curasight A/S
Official Site Inspections
http://www.curasight.com Semrush global rank: 8.34 M Semrush visits lastest month: 326
- Host name: 52.174.176.76
- IP address: 52.174.176.76
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Curasight A/S"
Curasight - Providing answers for cancer patients
Apr 4, 2025 Curasight is a pioneer in the field of exploiting a novel PET imaging target – the urokinase-type plasminogen activator receptor (uPAR) – for improved prostate cancer diagnose.See details»
About Us - Curasight
Apr 4, 2025 Curasight is a clinical stage biotech company committed to improving both diagnosis and the treatment of certain types of cancer. Utilizing its cutting-edge uPAR Theranostic …See details»
Management Team - Curasight
During her tenure at Azanta, she was the company responsible for the development program of a radiosensitizer in squamous cell cancer of the head and neck (SCCHN) and supported a phase III tripartite collaboration between …See details»
Curasight A/S - Crunchbase Company Profile & Funding
Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications.See details»
Curasight - LinkedIn
Curasight is built on more than a decade of research in PET imaging in cancer diseases at the University of Copenhagen and Rigshospitalet. Part of our company strategy is focused on the …See details»
Curasight A/S (NGM:CURAS) Company Profile & Overview
Feb 26, 2025 Company profile for Curasight A/S (NGM:CURAS) with a description, list of executives, contact details and other key facts.See details»
Curasight A/S - businessabc.net
Feb 25, 2025 Curasight A/S is a Danish medical technology company providing precision medicine services to oncologists and cancer clinics.See details»
Curasight Company Profile - Office Locations, Competitors ... - Craft
Curasight has 5 employees at their 1 location. See insights on Curasight including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Board of Directors - Curasight
Apr 9, 2025 CEO of DDD-Diagnostic A/S (2009 – 2015) Lars Trolle has been Chairman of the Board of Directors of Curasight A/S since 2014 and Deputy Chairman of the Board since 2020. …See details»
Curasight - Products, Competitors, Financials, Employees, …
Curasight Frequently Asked Questions (FAQ) When was Curasight founded? Curasight was founded in 2013. Where is Curasight's headquarters? Curasight's headquarters is located at …See details»
Curasight A/S - Drug pipelines, Patents, Clinical trials - Synapse
Explore Curasight A/S with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 11 news, Disease Domain:Neoplasms, Nervous System Diseases, Technology …See details»
Curasight Company Profile 2024: Stock Performance & Earnings
Information on stock, financials, earnings, subsidiaries, investors, and executives for Curasight. Use the PitchBook Platform to explore the full profile.See details»
Our Motivation - Curasight
Jan 21, 2025 This is why Curasight is pursuing the development of the uPAR Diagnostics and Therapy – and when combined known as Theranostics technology, where the diagnostics part …See details»
Curasight is on mission to improve the lives of millions of people …
Curasight is on mission to improve the lives of millions of people with cancer HCA Investor Seminar – 17. september 2024See details»
Curasight A/S - Funding, Financials, Valuation & Investors
Jun 1, 2017 Curasight is a biotech company focused on addressing the need for improved diagnosis and treatment of several cancer indications.See details»
Governance Curasight A/S - MarketScreener.com
Dec 31, 2012 Find the composition of the Board of Directors of Curasight A/S (NORDIC GROWTH MARKET Stock Exchange), the gender parity as well as the age distribution of the …See details»
Curasight. Information about the issuer. . News and credit ratings ...
Profile Curasight A/S operates as a biotechnology company. The Company focuses on exploiting a novel positron emissions tomography (PET) imaging platform targeting the urokinase-type …See details»
History - Curasight
Apr 8, 2025 The history of Curasight The lead uPAR-PET tracer candidate from this research developed into Curasight’s uTRACE® product for cancer diagnosis. At the same time …See details»
Curasight - Overview, News & Similar companies | ZoomInfo.com
Feb 22, 2024 View Curasight (www.curasight.com) location in Capital Region, Denmark , revenue, industry and description. Find related and similar companies as well as employees …See details»
Curasight as an investment - Curasight
Curasight is a Danish biotech company pioneering in the development of intelligent cancer imaging and more gentle and efficient treatment of cancer, using nuclear medicine. …See details»